mitoquinone

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• age-related macular degeneration [Insufficient Evidence]
• aging [Insufficient Evidence]
• Alzheimer disease [Possibly Ineffective]
• amyotrophic lateral sclerosis [Possibly Ineffective]
• angina [Insufficient Evidence]
• anthracycline-induced cardiotoxicity [Insufficient Evidence]
• anxiety [Insufficient Evidence]
• asthma [Insufficient Evidence]
• athletic performance [Likely Ineffective]
• autism spectrum disorder [Insufficient Evidence]
• bipolar disorder [Insufficient Evidence]
• BPH [Insufficient Evidence]
• breast CA [Insufficient Evidence]
• burns [Insufficient Evidence]
• cancer [Insufficient Evidence]
• cardiac event prevention, post-MI [Possibly Effective]
• cardiomyopathy, dilated [Insufficient Evidence]
• cardiomyopathy, hypertrophic [Insufficient Evidence]
• cardiovascular disease [Insufficient Evidence]
• cataracts, postop [Insufficient Evidence]
• cerebellar ataxia [Insufficient Evidence]
• CHF [Possibly Effective]
• chronic fatigue syndrome [Insufficient Evidence]
• cocaine dependence [Insufficient Evidence]
• coenzyme Q10 deficiency [Likely Effective]
• COPD [Insufficient Evidence]
• COVID-19 [Insufficient Evidence]
• critical illness (trauma) [Insufficient Evidence]
• cyclic vomiting syndrome [Insufficient Evidence]
• depression [Insufficient Evidence]
• diabetes mellitus [Possibly Ineffective]
• diabetic nephropathy [Insufficient Evidence]
• diabetic neuropathy [Possibly Effective]
• dry eye disease [Insufficient Evidence]
• erectile dysfunction [Insufficient Evidence]
• fatigue [Insufficient Evidence]
• fatigue, chemo-related [Possibly Ineffective]
• fibromyalgia [Possibly Effective]
• Friedreich ataxia [Insufficient Evidence]
• hearing loss [Insufficient Evidence]
• hepatitis C [Insufficient Evidence]
• hepatotoxicity, toxin-induced [Insufficient Evidence]
• HTN [Insufficient Evidence]
• Huntington disease [Likely Ineffective]
• hyperlipidemia [Insufficient Evidence]
• infertility in patients of childbearing potential [Insufficient Evidence]
• ischemic reperfusion injury [Possibly Effective]
• lichen planus [Insufficient Evidence]
• male infertility [Insufficient Evidence]
• maternally inherited diabetes mellitus and deafness [Insufficient Evidence]
• metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
• metabolic syndrome [Insufficient Evidence]
• migraine prophylaxis [Possibly Effective]
• mitochondrial myopathies [Insufficient Evidence]
• multiple sclerosis [Possibly Effective]
• muscular dystrophy [Possibly Effective]
• myalgia, statin-induced [Insufficient Evidence]
• myocarditis [Insufficient Evidence]
• myopathy, statin-induced [Insufficient Evidence]
• obesity [Insufficient Evidence]
• Parkinson disease [Possibly Ineffective]
• periodontitis [Insufficient Evidence]
• Peyronie disease [Possibly Effective]
• physical performance [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• post-polio syndrome [Possibly Ineffective]
• Prader-Willi syndrome [Insufficient Evidence]
• pre-eclampsia [Insufficient Evidence]
• renal failure [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• sepsis [Insufficient Evidence]
• tooth extraction [Insufficient Evidence]
• ulcerative colitis [Insufficient Evidence]
• wound healing [Insufficient Evidence]
• wrinkled skin [Insufficient Evidence]
• xerostomia [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

ADHD, peds patients

[Insufficient Evidence]

Dose: 1-3 mg/kg/dose PO qd; Info: for patients 6-16 yo; used with atomoxetine

age-related macular degeneration

[Insufficient Evidence]

Dose: 10 mg PO qd; Info: used with acetyl-L-carnitine and omega-3 fatty acids

angina

[Insufficient Evidence]

Dose: 60 mg PO qd; Alt: 50 mg PO tid

anthracycline-induced cardiotoxicity, peds patients

[Insufficient Evidence]

Dose: 100 mg PO bid; Info: for patients 3-12 yo

asthma

[Insufficient Evidence]

Dose: 120 mg PO qd; Info: may give in divided doses; used with conventional tx

autism spectrum disorder, peds patients

[Insufficient Evidence]

Dose: 50 mg PO bid; Start: 50 mg PO qd x7 days; Info: for patients 3-6 yo

bipolar disorder

[Insufficient Evidence]

Dose: 800 mg PO qd; Info: may give in divided doses

BPH

[Insufficient Evidence]

Dose: 100 mg PO qd; Info: used with L-carnitine and finasteride

cancer

[Insufficient Evidence]

Dose: 150 mg PO bid

cardiac event prevention, post-MI

[Possibly Effective]

Dose: 60 mg PO bid starting within 72h of MI; Alt: 250 mg NG x1, then 150 mg NG tid

cardiomyopathy, dilated

[Insufficient Evidence]

Dose: 3-10 mg/kg/day PO divided bid-tid; Alt: 10 mg/kg/dose PO qd; Info: for use in peds patients

cardiomyopathy, hypertrophic

[Insufficient Evidence]

Dose: 120-240 mg PO qd; Info: may give in divided doses

cardiovascular disease

[Insufficient Evidence]

Dose: 100 mg PO bid

cerebellar ataxia

[Insufficient Evidence]

Dose: 30 mg/kg/day PO qd; Info: may give in divided doses

CHF

[Possibly Effective]

Dose: 30-600 mg PO qd; Info: may give doses >100 mg/day in divided doses; used with conventional tx

chronic fatigue syndrome

[Insufficient Evidence]

Dose: 100 mg PO bid

coenzyme Q10 deficiency, adult patients

[Likely Effective]

Dose: 150-2400 mg/day PO divided qd-tid

coenzyme Q10 deficiency, peds patients

[Likely Effective]

Dose: 60-250 mg/day PO divided qd-tid; Alt: up to 30 mg/kg/day PO divided tid

COPD

[Insufficient Evidence]

Dose: 90 mg PO qd

COVID-19

[Insufficient Evidence]

Dose: 20 mg PO qd x14 days; Start: within 72h after exposure to COVID-19

critical illness (trauma)

[Insufficient Evidence]

Dose: 400 mg PO qd; Info: may give in divided doses

cyclic vomiting syndrome

[Insufficient Evidence]

Dose: 10 mg/kg/day PO divided bid; Max: 200 mg bid; Info: for use in adult and peds patients

depression

[Insufficient Evidence]

Dose: 100-500 mg PO qd; Alt: 5 mg/kg/day PO qd; Info: may give in divided doses; used with or without antidepressant

diabetic neuropathy

[Possibly Effective]

Dose: 400 mg PO qd; Alt: 100 mg PO tid; Info: may give doses >100 mg/day in divided doses; used with or without pregabalin

dry eye disease

[Insufficient Evidence]

Dose: 1 drop in eye(s) bid-qid; Info: 1:1 solution with cross-linked hyaluronic acid

fatigue

[Insufficient Evidence]

Dose: 60-500 mg PO qd; Info: may give doses >100 mg/day in divided doses

fibromyalgia

[Possibly Effective]

Dose: 300-400 mg PO qd; Info: may give in divided doses

Friedreich ataxia

[Insufficient Evidence]

Dose: 200 mg PO bid; Info: used with vitamin E

hearing loss

[Insufficient Evidence]

Dose: 160 mg PO qd; Info: may give in divided doses

hepatotoxicity, toxin-induced

[Insufficient Evidence]

Dose: 200 mg PO bid; Info: used with acetyl-L-carnitine and alpha-lipoic acid

HTN

[Insufficient Evidence]

Dose: 100-900 mg PO qd; Info: may give in divided doses; used with or without conventional tx

hyperlipidemia

[Insufficient Evidence]

Dose: 100-500 mg PO qd; Alt: 2 mg PO qd; Info: may give doses >100 mg/day in divided doses

ischemic reperfusion injury

[Possibly Effective]

Dose: 150-300 mg/day PO divided qd-tid x7-14 days before bypass or vascular surgery; Alt: 5 mg/kg/dose IV x1 given 2h before bypass or vascular surgery

lichen planus

[Insufficient Evidence]

Dose: 120 mg mucoadhesive tab topically tid

male infertility

[Insufficient Evidence]

Dose: 200-400 mg/day PO divided qd-bid; Alt: 10 mg PO tid; 20 mg PO bid; Info: may give doses >100 mg/day in divided doses

maternally inherited diabetes mellitus and deafness

[Insufficient Evidence]

Dose: 150 mg PO qd; Info: may give in divided doses

metabolic dysfunction-associated steatotic liver disease

[Insufficient Evidence]

Dose: 100 mg PO qd

migraine prophylaxis, adult patients

[Possibly Effective]

Dose: 100-400 mg PO qd; Info: may give in divided doses

migraine prophylaxis, peds patients

[Possibly Effective]

Dose: 1-3 mg/kg/dose PO qd; Alt: 100 mg PO qd; 30 mg PO qd if wt <30 kg; 60 mg PO qd if wt >30 kg

mitochondrial myopathies

[Insufficient Evidence]

Dose: 150-160 mg PO qd; Alt: 2 mg/kg/dose PO qd; Info: up to 3000 mg/day has been used; may give in divided doses

multiple sclerosis

[Possibly Effective]

Dose: 500 mg PO qd; Info: may give in divided doses

muscular dystrophy

[Possibly Effective]

Dose: 100 mg PO qd

myalgia, statin-induced

[Insufficient Evidence]

Dose: 100 mg PO qd-bid

myocarditis

[Insufficient Evidence]

Dose: 10 mg PO tid

myopathy, statin-induced

[Insufficient Evidence]

Dose: 100 mg PO bid; Alt: 60 mg PO qid

periodontitis

[Insufficient Evidence]

Dose: 50 mg PO qd; Alt: apply gel topically into the periodontal pocket qd

Peyronie disease

[Possibly Effective]

Dose: 300 mg PO qd; Info: may give in divided doses

polycystic ovary syndrome

[Insufficient Evidence]

Dose: 100-200 mg PO qd; Info: may give in divided doses

Prader-Willi syndrome, peds patients

[Insufficient Evidence]

Dose: 2.5 mg/kg/dose PO qd

pre-eclampsia

[Insufficient Evidence]

Dose: 100 mg PO bid until term or delivery; Start: 20 wk gestation

renal failure

[Insufficient Evidence]

Dose: 180 mg PO qd; Info: may give in divided doses

tooth extraction

[Insufficient Evidence]

Dose: 100 mg PO qd

ulcerative colitis

[Insufficient Evidence]

Dose: 100 mg PO bid

wrinkled skin

[Insufficient Evidence]

Dose: apply 1% cream topically bid

xerostomia

[Insufficient Evidence]

Dose: 100 mg PO qd